These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24909701)

  • 1. Febrile neutropaenia and chemotherapy discontinuation in women aged 70 years or older receiving adjuvant chemotherapy for early breast cancer.
    Adjogatse D; Thanopoulou E; Okines A; Thillai K; Tasker F; Johnston SR; Harper-Wynne C; Torrisi E; Ring A
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):692-6. PubMed ID: 24909701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
    J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary function testing in women with breast cancer treated with radiotherapy and chemotherapy.
    Spyropoulou D; Leotsinidis M; Tsiamita M; Spiropoulos K; Kardamakis D
    In Vivo; 2009; 23(5):867-71. PubMed ID: 19779125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.
    Bonneterre J; Révillion F; Desauw C; Blot E; Kramar A; Fournier C; Hornez L; Peyrat JP
    Oncol Rep; 2013 Jan; 29(1):355-61. PubMed ID: 23117275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population.
    Redana S; Sharp A; Lote H; Mohammed K; Papadimitraki E; Capelan M; Ring A
    Breast; 2016 Dec; 30():13-18. PubMed ID: 27569021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen.
    Meattini I; Livi L; Saieva C; Franceschini D; Scotti V; Mangoni M; Loi M; Di Brina L; Zei G; Bonomo P; Greto D; Gelain E; Nori J; Sanchez LJ; Orzalesi L; Bianchi S; Biti G
    Clin Breast Cancer; 2013 Aug; 13(4):247-53. PubMed ID: 23684167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
    Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
    Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer.
    Manga GP; Shahi PK; Ureña MM; Pereira RQ; Plaza MI; Peron YI; Val RG; Carrión JB; Cañón EP; Alfonso PG
    Breast Cancer; 2010 Jul; 17(3):205-11. PubMed ID: 19551465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Febrile Neutropenia Rates According to Body Mass Index and Dose Capping in Women Receiving Chemotherapy for Early Breast Cancer.
    Lote H; Sharp A; Redana S; Papadimitraki E; Capelan M; Ring A
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):597-603. PubMed ID: 26936608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
    Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
    Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of treatment related death and febrile neutropaenia with first line palliative chemotherapy for de novo metastatic breast cancer in clinical practice in a middle resource country.
    Phua CE; Tang WH; Yusof MM; Saad M; Alip A; See MH; Taib NA
    Asian Pac J Cancer Prev; 2014; 15(23):10263-6. PubMed ID: 25556458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging.
    Tsunoda-Shimizu H; Hayashi N; Hamaoka T; Kawasaki T; Tsugawa K; Yagata H; Kikuchi M; Suzuki K; Nakamura S
    Breast Cancer; 2008; 15(2):133-40. PubMed ID: 18288570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
    Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
    J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer at diagnosis.
    Park S; Park JM; Cho JH; Park HS; Kim SI; Park BW
    Ann Surg Oncol; 2013 Sep; 20(9):2858-65. PubMed ID: 23645483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.